Aegis Positive on Synergy Pharma (SGYP); Approved to Move Plecanatide into IBS-C Treatment Phase 3
Tweet Send to a Friend
Aegis Capital affirms Synergy Pharmaceuticals (Nasdaq: SGYP) at Buy with a target price of $26 following news that the FDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE